Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;8(3):192-202.
doi: 10.1177/1756287216637569. Epub 2016 Mar 22.

Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence

Affiliations
Review

Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence

Elizabeth J Traore et al. Ther Adv Urol. 2016 Jun.

Abstract

Objectives: Peyronie's disease (PD) is a connective tissue disorder resulting in the abnormal accumulation of scar or plaques in the tunica albuginea of the penis. The condition is characterized by two phases: an active, inflammatory phase, and a stable, chronic phase. Collagenase Clostridium histolyticum (CCH) was isolated in the mid-1900s and postulated as a potential pharmacologic strategy for breaking down the abnormal connective tissue plaques of PD. Prior to the introduction of CCH, a wide variety of treatment modalities for PD were used in clinical practice, including oral and topical medications, intralesional injections, electromotive drug administration, extracorporeal shockwave therapy, traction, and invasive surgery, all with variable results. This review aims to examine the known data surrounding the use of intralesional CCH injections in the treatment of PD.

Methods: CCH is a recently US Food and Drug Administration approved pharmacologic treatment for PD. Clinical trials using intralesional CCH injection therapy for the treatment of PD were reviewed for clinical safety and efficacy of treatment.

Results: Studies demonstrated that CCH treatment administered in multiple cycles led to significant benefit in both the psychological and physical aspects of PD. The strongest evidence for CCH's effectiveness was revealed in large, multicenter randomized controlled trials (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies I and II) in which intralesional CCH was combined with manual modeling of the penis. Although adverse events from treatment are relatively common, the majority are mild to moderate in degree, including penile pain, swelling, and bruising, which all resolve spontaneously.

Conclusion: Overall, evidence indicates that CCH is a valuable, effective, and safe minimally invasive treatment option for men with PD.

Keywords: Collagenase Clostridium histolyticum; Peyronie’s Disease Questionnaire; Peyronie’s disease; penile curvature; penile plaque.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: EJT, WW, and FAY report no conflict of interest in this work. WJGH was the primary investigator for the IMPRESS studies and is on the advisory board for Endo Pharmaceuticals.

Similar articles

Cited by

References

    1. Arafa M., Eid H., El-Badry A., Ezz-Eldine K., Shamloul R. (2007) The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res 19: 213–217. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16915304 (accessed 23 October 2015). - PubMed
    1. Auxilium Pharmaceuticals Inc. (2014) Xiaflex® (Collagenase Clostridium histolyticum) [prescribing information]. 1–42.
    1. Berookhim B., Choi J., Alex B., Mulhall J. (2014) Deformity stabilization and improvement in men with untreated Peyronie’s disease. BJU Int 113: 133–136. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24053665 (accessed 23 October 2015). - PubMed
    1. Carson C., 3rd, Sadeghi-Nejad H., Tursi J., Smith T., Kaufman G., Gilbert K., et al. (2015) Analysis of the clinical safety of intralesional injection of collagenase clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int 116: 815–822. - PubMed
    1. Chilton C., Castle W., Westwood C., Pryor J. (1982) Factors associated in the aetiology of Peyronie’s disease. Br J Urol 54: 748–750. - PubMed